Current and future drug-eluting coronary stent technology
Authors:
- Alfonso IelasiAIAlfonso Ielasi
- Azeem LatibAzeem Latib
- Antonio ColomboACAntonio Colombo
- 1 April 2011
- journal article
- review article
- Published by Taylor & Francis in Expert Review of Cardiovascular Therapy
- Vol. 9 (4) , 485-503
Abstract
Despite the impressive benefits obtained following the introduction of the drug-eluting stent, safety concerns have been raised over their long-term safety with particular regard to stent thrombosis. Various mechanisms such as delayed endothelialization, local hypersensitivity and endothelial dysfunction owing to the durable polymer coating and/or the drug itself have been suggested as possible causes of this phenomenon. Therefore, to address these concerns, a newer-generation of drug-eluting stents has been developed and they are currently undergoing preclinical and clinical evaluation in order to increase both the safety and biocompatibility by optimizing the three major components of drug-eluting stents: the stent platform, the polymer and the drug. This article critically reviews the key clinical trials and the current status of these new coronary devices as well as preventing future perspectives for their continued development.Keywords
This publication has 70 references indexed in Scilit:
- Six-Month Results of the NEVO RES-ELUTION I (NEVO RES-I) TrialCirculation: Cardiovascular Interventions, 2010
- Comparison of Zotarolimus-Eluting and Everolimus-Eluting Coronary StentsNew England Journal of Medicine, 2010
- Development of a Novel Prohealing Stent Designed to Deliver Sirolimus From a Biodegradable Abluminal MatrixCirculation: Cardiovascular Interventions, 2010
- 2-Year Clinical and Angiographic Outcomes From a Randomized Trial of Polymer-Free Dual Drug-Eluting Stents Versus Polymer-Based Cypher and Endeavor, Drug-Eluting StentsJACC, 2010
- Polymer-Free Biolimus A9-Coated Stent Demonstrates More Sustained Intimal Inhibition, Improved Healing, and Reduced Inflammation Compared With a Polymer-Coated Sirolimus-Eluting Cypher Stent in a Porcine ModelCirculation: Cardiovascular Interventions, 2010
- Rationale and design of the Patient Related OuTcomes with Endeavor versus Cypher stenting Trial (PROTECT): Randomized controlled trial comparing the incidence of stent thrombosis and clinical events after sirolimus or zotarolimus drug-eluting stent implantationAmerican Heart Journal, 2009
- Genous™ endothelial progenitor cell capturing stent vs. the Taxus Liberté stent in patients with de novo coronary lesions with a high-risk of coronary restenosis: a randomized, single-centre, pilot studyEuropean Heart Journal, 2009
- Correlation of Intravascular Ultrasound Findings With Histopathological Analysis of Thrombus Aspirates in Patients With Very Late Drug-Eluting Stent ThrombosisCirculation, 2009
- Randomized Comparison of the Nobori Biolimus A9-Eluting Coronary Stent With the Taxus Liberté Paclitaxel-Eluting Coronary Stent in Patients With Stenosis in Native Coronary ArteriesCirculation: Cardiovascular Interventions, 2009
- Coating irregularities of durable polymer-based drug-eluting stents as assessed by scanning electron microscopyEuroIntervention, 2009